The IPTA Nashville consensus conference on post-transplant lymphoproliferative disorders after solid organ transplantation in children: IV-consensus guidelines for the management of post-transplant lymphoproliferative disorders in children and adolescents.

Autor: Allen UD; Division of Infectious Diseases, Department of Paediatrics, Transplant and Regenerative Medicine Center, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada., L'Huillier AG; Pediatric Infectious Diseases Unit and Laboratory of Virology, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland., Bollard CM; Center for Cancer and Immunology Research, Children's National Hospital, The George Washington University, Washington, District of Columbia, USA., Gross TG; Center for Cancer and Blood Diseases, Children's Hospital Colorado, Aurora, Colorado, USA., Hayashi RJ; Division of Pediatric Hematology/Oncology, St. Louis Children's Hospital, Washington University School of Medicine, St. Louis, Missouri, USA., Höcker B; Department of Pediatrics I, Medical Faculty, University Children's Hospital, Heidelberg University, Heidelberg, Germany., Maecker-Kolhoff B; Hannover Medical School, Pediatric Hematology and Oncology, Hannover, Germany., Marks SD; Department of Paediatric Nephrology, Great Ormond Street Hospital for Children NHS Foundation Trust, NIHR Great Ormond Street Hospital Biomedical Research Centre, London, UK., Mazariegos GV; Hillman Center for Pediatric Transplantation, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA.; Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA., Smets F; Pediatric Gastroenterology and Hepatology, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium., Trappe RU; Department of Hematology and Oncology, DIAKO Ev. Diakonie-Krankenhaus Bremen, Bremen, Germany.; Department of Internal Medicine II: Hematology and Oncology, University Medical Centre Schleswig-Holstein, Kiel, Germany., Visner G; Division of Pulmonary Medicine, Boston Children's Hospital/Harvard Medical School, Boston, Massachusetts, USA., Chinnock RE; Loma Linda University Children's Hospital, Loma Linda, California, USA., Comoli P; Cell Factory & Pediatric Hematology/Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy., Danziger-Isakov L; Division of Infectious Disease, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio, USA., Dulek DE; Division of Pediatric Infectious Diseases, Monroe Carell Junior Children's Hospital at Vanderbilt and Vanderbilt University Medical Center, Nashville, Tennessee, USA., Dipchand AI; Department of Paediatrics, Labatt Family Heart Centre, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada., Ferry JA; Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA., Martinez OM; Department of Surgery and Program in Immunology, Stanford University School of Medicine, Stanford, California, USA., Metes DM; Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Michaels MG; Division of Pediatric Infectious Diseases, UPMC Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA., Preiksaitis J; Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada., Squires JE; Division of Gastroenterology, Hepatology and Nutrition, UPMC Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA., Swerdlow SH; Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA., Wilkinson JD; Department of Pediatrics, Vanderbilt School of Medicine, Nashville, Tennessee, USA., Dharnidharka VR; Division of Pediatric Nephrology, Hypertension & Apheresis, Department of Pediatrics, Washington University School of Medicine and St. Louis Children's Hospital, St. Louis, Missouri, USA., Green M; Division of Pediatric Infectious Diseases, UPMC Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA., Webber SA; Department of Pediatrics, Vanderbilt School of Medicine, Nashville, Tennessee, USA., Esquivel CO; Stanford University School of Medicine, Stanford, California, USA.
Jazyk: angličtina
Zdroj: Pediatric transplantation [Pediatr Transplant] 2024 Aug; Vol. 28 (5), pp. e14781.
DOI: 10.1111/petr.14781
Abstrakt: The International Pediatric Transplant Association convened an expert consensus conference to assess current evidence and develop recommendations for various aspects of care relating to post-transplant lymphoproliferative disorders (PTLD) after pediatric solid organ transplantation. This report addresses the outcomes of deliberations by the PTLD Management Working Group. A strong recommendation was made for reduction in immunosuppression as the first step in management. Similarly, strong recommendations were made for the use of the anti-CD20 monoclonal antibody (rituximab) as was the case for chemotherapy in selected scenarios. In some scenarios, there is uncoupling of the strength of the recommendations from the available evidence in situations where such evidence is lacking but collective clinical experiences drive decision-making. Of note, there are no large, randomized phase III trials of any treatment for PTLD in the pediatric age group. Current gaps and future research priorities are highlighted.
(© 2024 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: